X-linked severe combined immunodeficiency

X-SCID / Severe combined immunodeficiency, X-linked / IL2RG-related SCID

8.9
Overall
Confidence: 70%
Composite of urgency, severity, and feasibility — higher score indicates greater research priority
MONDO:MONDO:0011519IL2RG ↗

X-linked SCID accounts for approximately 40-50% of severe combined immunodeficiency cases worldwide; incidence of all SCID is roughly 1 in 50,000 to 1 in 100,000 births, with higher detection in regions with newborn screening.

Drugs in Pipeline
32
17 Phase 2 · 3 Phase 1
→
Clinical Trials
42
13 recruiting · 3 active · 13 completed · 13 other
→
Evidence Sources (1)
NIH / Orphanet↗

Last updated: March 26, 2026

Data sources: ClinVar 2026-03 · gnomAD v4.1 · ClinicalTrials.gov API v2 · MONDO:MONDO:0011519